GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc. (GNPX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C+ (2.5) | C (2.5) | D- (0.8) | C+ (2.6) | C (2.2) |
| 2026-11-05 | C+ (2.5) | C+ (2.5) | C+ (2.5) | D- (0.8) | C+ (2.7) | C (2.2) |
| 2026-10-29 | C+ (2.5) | C+ (2.5) | C+ (2.6) | F (0.5) | C+ (2.7) | C- (2.1) |
| 2026-10-22 | C+ (2.5) | C+ (2.5) | C+ (2.5) | F (0.4) | C+ (2.6) | C- (2.1) |
| 2026-10-15 | C+ (2.5) | C+ (2.5) | C+ (2.5) | F (0.4) | C+ (2.6) | C- (2.1) |